Self-contained synthetic E. coli resistant to viral infection could prove invaluable to the biotechnology industry by increasing product consistency and reducing safety concerns.
Danielle Gerhard, PhD | Mar 22, 2024 | 10+ min read
With the help of directed evolution, scientists inch closer to developing viral vectors that can cross the human blood-brain barrier to deliver gene therapy.